Platform technology

SagittaTM

Developing Targeted Therapies With no Compromise ​

SagittaTM Bir and SagittaTM Dui are discovered to address this challenge with biodegradable conjugation platforms that reinforce ideal performances in terms of the therapeutic index, PK and manufacturability.  

SagittaTM

Developing Targeted Therapies With no Compromise

SagittaTM Bir and SagittaTM Dui are discovered to address this challenge with biodegradable conjugation platforms that reinforce ideal performances in terms of the therapeutic index, PK and manufacturability.  

HIGHER

Therapeutic Index

The dual drug loading capacity of SagittaTM yields to a synergistic therapeutic effect. SagittaTM platform is compatible with a wide range of targeting ligands or mAbs as well as a diverse choice of drugs – ensuring highest efficacy and specificity.

IMPROVED

Pharmacokinetics

SagittaTM platform significantly prolongs the circulation time compared to native API. The improvement in half-life translated across species and therefore poses predictable promise for later clinical stages.

STRAIGHT-FORWARD

Manufacturing

We manufacture our products at our own GMP certificated production facility for clinical batch lyophilized oncology drugs.

Efficacy & Specificity

Efficacy & Specificity

· Versatile structure ·
· Synergistic therapeutic effect ·
· Higher accumulation ·

Translatability

Translatability

· Pharmacokinetic parameters ·
· Predictable translation to human ·

Tolerability

Tolerability

· Reduced side effect profile ·
· Enhanced Permeability & Retention effect ·
· Selective release ·
· Biologic stimuli driven release ·

Manufacturability

Manufacturability

· Proven GMP production record ·
· High purity ·
· Scalable for clinical GMP batches ·

HIGHER

THERAPEUTIC INDEX

The dual drug loading capacity of SagittaTM yields to a synergistic therapeutic effect. SagittaTM platform is compatible with a wide range of targeting ligands or mAbs as well as a diverse choice of drugs – ensuring highest efficacy and specificity.

IMPROVED

PHARMACOKINETICS

SagittaTM platform significantly prolongs the circulation time compared to native API. The improvement in half-life translated across species and therefore poses predictable promise for later clinical stages.

 STRAIGHT-FORWARD

MANUFACTURING

We manufacture our products at our own GMP certificated production facility for clinical batch lyophilized oncology drugs.

Efficacy & Specificity

Efficacy & Specificity

· Versatile structure
· Synergistic therapeutic effect
· Higher accumulation

Tolerability

Tolerability

· Reduced side effect profile
· Enhanced Permeability & Retention effect
· Selective release
· Biologic stimuli driven release

Translatability

Translatability

· Pharmacokinetic parameters
· Predictable translation to human

Manufacturability

Manufacturability

· Proven GMP production record
· High purity
· Scalable for clinical GMP batches